Preclinical Pharmacology in the Rhesus Monkey of CW 1759-50, a New Ultra-short Acting Nondepolarizing Neuromuscular Blocking Agent, Degraded and Antagonized by L-Cysteine
暂无分享,去创建一个
H. Sunaga | P. Heerdt | J. Savarese | W. Wastila | M. Belmont | Jeff D. McGilvra | Erin Jeannotte | M. Murrell | Farrell E Cooke
[1] C. Lien,et al. Dose–response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man , 2016, Anesthesiology.
[2] H. Sunaga,et al. Preclinical Pharmacology of CW002: A Nondepolarizing Neuromuscular Blocking Drug of Intermediate Duration, Degraded and Antagonized by l-cysteine—Additional Studies of Safety and Efficacy in the Anesthetized Rhesus Monkey and Cat , 2016, Anesthesiology.
[3] H. Sunaga,et al. Novel neuromuscular blocking drugs and antagonists , 2015, Current opinion in anaesthesiology.
[4] H. Sunaga,et al. Rapid Chemical Antagonism of Neuromuscular Blockade by l-Cysteine Adduction to and Inactivation of the Olefinic (Double-bonded) Isoquinolinium Diester Compounds Gantacurium (AV430A), CW 002, and CW 011 , 2010, Anesthesiology.
[5] Edward J Yoon,et al. Cysteine Reversal of the Novel Neuromuscular Blocking Drug CW002 in Dogs: Pharmacodynamics, Acute Cardiovascular Effects, and Preliminary Toxicology , 2010, Anesthesiology.
[6] H. Sunaga,et al. Pharmacodynamics and Cardiopulmonary Side Effects of CW002, a Cysteine-reversible Neuromuscular Blocking Drug in Dogs , 2010, Anesthesiology.
[7] C. Lien,et al. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. , 2009, Journal of critical care.
[8] S. Lorenzini,et al. Age-related influence on thiol, disulfide, and protein-mixed disulfide levels in human plasma. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.
[9] C. Meistelman,et al. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[10] Sanjay S. Patel,et al. Preclinical Pharmacology of GW280430A (AV430A) in the Rhesus Monkey and in the Cat: A Comparison with Mivacurium , 2004, Anesthesiology.
[11] Sanjay S. Patel,et al. Clinical Pharmacology of GW280430A in Humans , 2004, Anesthesiology.
[12] D. Bevan. The new relaxants: are they worth it? , 1999, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[13] J. A. Ray,et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers. , 1999, Journal of medicinal chemistry.
[14] Boswell,et al. Bis- and mixed-tetrahydroisoquinolinium chlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers , 1999, Journal of medicinal chemistry.
[15] C. Lien,et al. The Cardiovascular Effects and Histamine-Releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1996 .
[16] J. Savarese,et al. Comparative Pharmacology of Cisatracurium (51W89), Atracurium, and Five Isomers in Cats , 1996, Anesthesiology.
[17] C. Lien,et al. The Cardiovascular Effects and Histamine‐releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1995, Anesthesiology.
[18] H. H. Ali,et al. The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. , 1989, Anesthesiology.
[19] W. Bowman,et al. Structure: action Relationships Among Some Desacetoxy Analogues of Pancuronium and Vecuronium in the Anesthetized Cat , 1988, Anesthesiology.
[20] H. H. Ali,et al. The Clinical Pharmacology of Metocurine: Dimethyltubocurarine Revisited , 1977, Anesthesiology.